Compare RAND & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAND | ATNM |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 36.8M |
| IPO Year | 1996 | 2013 |
| Metric | RAND | ATNM |
|---|---|---|
| Price | $12.15 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.3K | ★ 115.6K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.87% | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $1.02 |
| 52 Week High | $26.00 | $1.95 |
| Indicator | RAND | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 52.28 |
| Support Level | $10.56 | $1.02 |
| Resistance Level | $12.50 | $1.71 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 93.29 | 77.78 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.